Wed, Nov 06, 2024
Mankind Pharma, one of India’s largest pharmaceutical players, witnessed its shares surge by 6 per cent to a peak of Rs 2,882.75 on the BSE after announcing a robust 29 per cent year-on-year profit growth for the quarter ending September 2024.
More >
Tue, Nov 05, 2024
Mankind Pharma Q2 Results: Mankind Pharma on Tuesday reported a 29 per cent rise in its consolidated net profit to Rs 658.88 crore for the second quarter ended September 2024, helped by recovery in volume.
Thu, Oct 24, 2024
BSV, has developed recombinant and niche biologic products in-house, demonstrating its strong R&D capabilities and boasts of a robust branded product portfolio across women's health, fertility, critical care and immunoglobulins.
Fri, Sep 20, 2024
Mankind Pharma's board on Friday approved a proposal to raise up to Rs 10,000 crore through bonds.
Wed, Sep 18, 2024
The company, however, did not mention the amount it seeks to raise through the issue of securities.
Fri, Jul 26, 2024
The company has entered into a definitive agreement with Advent to acquire a 100 per cent stake in Bharat Serums and Vaccines (BSV) for an enterprise value of around Rs 13,630 crore, Mankind Pharma said in a statement.
Thu, Jul 11, 2024
Which stocks will be in focus today Raymond, Bajaj Consumer Care, Zydus Lifesciences Ltd & Mankind Pharma? News shares and triggers. Know about Stocks In News.
Wed, Jul 10, 2024
Vedanta, Bajaj Healthcare, Poly cab & Mankind Pharma, which stocks will be in focus today? News shares and triggers. Know in Stocks In News.
As 0.9 per cent equity changed hands in the pre-opening deal, shares of Mankind Pharma will gain focus today.
Thu, Jun 13, 2024
Stock of the Day; Today Anil Singhvi gave buying advice in Ambuja Cement Futures & Mankind Pharma. What is stoploss and targets? See in this video.
Thu, May 16, 2024
Stock of the Day: Today Anil Singhvi gave buying opinion in Mankind Pharma...What is the stoploss and targets? See in this video...
Mankind Pharma Share Price Target, Mankind Pharma Share 4 Results: Revenue from operations rose to Rs 2,441 crore in the period under review from Rs 2,053 crore in the year-ago period, Mankind Pharma said in a statement.
Wed, May 15, 2024
Revenue from operations rose to Rs 2,441 crore in the period under review from Rs 2,053 crore in the year-ago period, Mankind Pharma said in a statement.
Thu, Apr 18, 2024
Which stocks will be entered in MSCI? Where will the investment come from entry in MSCI? Which stocks will be out of MSCI? Know complete details in this video
Tue, Mar 26, 2024
Nifty at the close gave up 92.05 points, or 0.42 per cent, and ended at 22,004.7, while Sensex fell 361.64 points, or 0.5 per cent, and settled at 72,470.30.
Mankind Pharma share price NSE BSE, Mankind Pharma block deals: Beige Limited, a private equity firm affiliated with ChrysCapital, is the likely seller. The size of the deal, as per Zee Business Research, was Rs 2,450 crore.
Fri, Mar 22, 2024
Mankind Pharma Share Price Target: Anil Singhvi said that Mankind Pharma has a stronghold in the pharma market as they have around 40 brands, many of which are market leaders.
Thu, Feb 08, 2024
Promoters of Mankind Pharma will sell their 1.62% stake, or 64.90 lakh shares, through the block deal. The floor price of the share has been fixed at Rs 2050/share for the deal.
Wed, Jan 31, 2024
Mankind Pharma Q3 Results: Mankind Pharma on Wednesday said its consolidated net profit increased 55 per cent to Rs 460 crore for the third quarter ended December 2023.
Thu, Jan 11, 2024
Mankind Pharma Share Price: According to Kunal Saraogi of Equityrush, investors should buy this pharma stock at every dip.
Tue, Dec 12, 2023
Big Block Deal in MankindPharma - What are the chances of getting included in MSCI index? Floor price of block deal is ₹ 1785.65/share. If it gets included in MSCI, it will be a big investment? - Know the complete details from Varun...
Mankind Pharma's stock took a nosedive in the early morning trading on Dec 12 after the company announced a massive block deal worth Rs 4,935 crore. This news has investors worried, and the stock is currently down over 4%. In this video, we'll explore the details of this block deal, its impact on Mankind Pharma's future, and what it means for your investment.
The stock was trading down by 4.40 per cent, or Rs 84.35, at Rs 1834.40 at 9:19 am on Tuesday after the pharma company said it would launch the block deal at Rs 1785.65 per share, or at a 7 per cent discount from LTP.
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
